Cytheris has received Notice of Allowance from the US Patent and Trademark Office (USPTO), for its patent application IL-7 Drug Substance, Composition, Preparation and Uses, US Patent Application Number 10/522,883.
This patent covers IL-7 pharmaceutical composition which should contain not only the specific IL-7 conformer as the major constituent, but also be devoid of other conformers or IL-7 molecular variants. IL-7 plays a pivotal role in supporting T-cell expansion and function.
As the exclusive licensee, Cytheris holds all original patents protecting IL-7 and various uses including the use for T cell expansion and for enhancing humoral and cellular immunity.
Michel Morre, President and CEO of Cytheris, said: We are pleased to announce receipt of this Notice of Allowance by the USPTO. Once issued, this patent along with other previously issued patents will provide broad protection for Cytheris’ recombinant human interleukin-7 (CYT107), a critical immune-modulator for immune T-cell recovery and enhancement, and extend this protection in the US to 2022.”